Lv3
260 积分 2023-11-13 加入
中国6364例结直肠癌患者 KRAS 基因突变检测分析
2天前
已完结
KRAS mutation in pancreatic cancer
2天前
已完结
Targeting KRAS in cancer
11天前
已完结
Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer
18天前
已完结
Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer
2个月前
已完结
肺癌脑转移中国治疗指南(2021年版)
2个月前
已完结
Chinese innovative drug R&D trends in 2024
2个月前
已完结
Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study
2个月前
已完结
Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study
4个月前
已完结
PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment
4个月前
已完结
皖公网安备34019202002308
